Kadhi Ayat, Mohammed Fathima, Nemer Georges
Division of Genomics and Translational Biomedicine, College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.
Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Front Cardiovasc Med. 2021 Apr 14;8:613295. doi: 10.3389/fcvm.2021.613295. eCollection 2021.
Heart failure (HF) is a global public health threat affecting 26 million individuals worldwide with an estimated prevalence increase of 46% by 2030. One of the main causes of HF and sudden death in children and adult is Dilated Cardiomyopathy (DCM). DCM is characterized by dilation and systolic dysfunction of one or both ventricles. It has an underlying genetic basis or can develop subsequent to various etiologies that cause myocardium inflammation (secondary causes). The morbidity and mortality rates of DCM remains high despite recent advancement to manage the disease. New insights have been dedicated to better understand the pathogenesis of DCM in respect to genetic and inflammatory basis by linking the two entities together. This cognizance in the field of cardiology might have an innovative approach to manage DCM through targeted treatment directed to the causative etiology. The following review summarizes the genetical and inflammatory causes underlying DCM and the pathways of the novel precision-medicine-based immunomodulatory strategies to salvage and prevent the associated heart failure linked to the disease.
心力衰竭（HF）是一种全球性公共卫生威胁，影响着全球2600万人，预计到2030年患病率将增加46%。儿童和成人HF及猝死的主要原因之一是扩张型心肌病（DCM）。DCM的特征是一个或两个心室扩张和收缩功能障碍。它有潜在的遗传基础，或可继发于各种导致心肌炎症的病因（继发性病因）。尽管最近在疾病管理方面取得了进展，但DCM的发病率和死亡率仍然很高。通过将遗传和炎症两个实体联系起来，人们致力于获得新的见解，以便更好地了解DCM在遗传和炎症基础方面的发病机制。心脏病学领域的这一认识可能会有一种创新方法，即通过针对病因的靶向治疗来管理DCM。以下综述总结了DCM潜在的遗传和炎症原因，以及基于新型精准医学的免疫调节策略的途径，以挽救和预防与该疾病相关的心力衰竭。
